Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: J Cardiovasc Pharmacol Ther. 2015 Jun 30;21(2):177–186. doi: 10.1177/1074248415591700

Figure 2.

Figure 2

BIX02565 inhibits serum enhanced but not the basal Na+/H+ exchanger 1 (NHE1) activity. H9C2 cells were serum starved (0% fetal bovine serum [FBS]) for 24 hours and kept in the presence of 10% FBS (——) or 0% FBS (— —) for recording the enhanced and basal NHE1 activity (measured by the rate of intracellular pH [pHi] recovery). BIX 02565 was titrated to the cells with (—▲—) and without FBS (—●—). The 10% FBS-stimulated NHE1 activity was calibrated as 100%. The NHE1 activity under all the other treatments was calibrated as a ratio to the 10% FBS treatment. BIX 02565 inhibited serum-enhanced NHE1 activity in a dose-dependent manner while had no effect on basal NHE1 activity.